DMAC — DiaMedica Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$6.45
+$0.10 (+1.57%)
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on NASDAQ. It is led by Dietrich John Pauls MBA, based in 301 Carlson Parkway, Minneapolis, MN, United States, 55305, with about 27 employees. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Net income was -$8.6M. DMAC currently screens at market cap $157.4M.
Use this DMAC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DMAC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DMAC SEC filings page. Lician reads the product cache first so this HTML stays unique to DiaMedica Therapeutics Inc even when a live quote feed is slow.
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DMAC Key Statistics
Market Cap
$157.38M
Volume
130,944
Previous Close
$6.74
Day Range
$6.60 – $6.87
EPS
$0.00
Revenue
$0.00
Net Income
-$24.44M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
27
DMAC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$24.44M | -$19.38M | -$13.68M | -$13.59M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets
$46.34M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.02M
Operating Cash Flow
-$22.08M
Free Cash Flow
$0.00
DiaMedica Therapeutics Inc Company Information
- President, CEO & Director
- Dietrich John Pauls MBA
- Headquarters
- 301 Carlson Parkway, Minneapolis, MN, United States, 55305
- Website
- www.diamedica.com
- Phone
- 763 496 5454
- IPO / Founded
- 2008-01-04
- Sector
- Healthcare
- Industry
- Biotechnology